Lecure

Lecure is a South Korean biotechnology company specializing in the development of next-generation microbiome-based therapeutics. The company focuses on leveraging Akkermansia muciniphila and other beneficial gut bacteria to treat metabolic and inflammatory diseases, including obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Lecure utilizes a proprietary platform for the isolation, anaerobic cultivation, and formulation of live biotherapeutic products (LBPs). Their research aims to restore gut health and modulate systemic metabolism through targeted microbial interventions that strengthen the intestinal barrier. The company is currently advancing its lead candidates through early clinical development, positioning itself as a leader in the therapeutic application of strictly anaerobic commensal bacteria.